Share on LinkedInShare on LinkedIn

ARTICLE · 03 DECEMBER 2020

New Court Proceedings - 2020

Smart & Biggar
Explore more from Smart & Biggar

INVEGA SUSTENNA (paliperidone palmitate): Janssen v Pharmascience.

CanadaLitigation, Mediation & Arbitration
Smart & Biggar
Smart & Biggar
Author LinkedIn connections

PMNOC Proceedings

INVEGA SUSTENNA (paliperidone palmitate): Janssen v Pharmascience

Judicial Review Proceedings

Innovative Medicines, AbbVie, Amgen, Astellas,  AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Gilead, Hoffmann-La Roche, Ipsen Biopharmaceuticals, Lundbeck, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Purdue, Sanofi-Aventis, Sunovion & Takeda v The Attorney General of Canada

For complete details about these proceedings, click here.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

View source

Related Articles

Read more about

Related Comparative Guides

See more popular content from

Article

Can An Arbitration Agreement Preclude Appeals, Even With Errors Of Law?

An Ontario court ruled that arbitration agreements containing "final and binding" language may prevent parties from appealing legal errors made by arbitrators. The decision examines how a $3 million construction dispute was resolved through arbitration, and why the losing party could not challenge the arbitrator's legal mistakes despite their significant financial impact.
CanadaLitigation, Mediation & Arbitration
McCarthy Tétrault
McCarthy Tétrault
Article

Boeing and Securities Class Certification: Trends in the United States and Canada

A U.S. appeals court has unanimously overturned certification of a securities class action against Boeing, establishing that plaintiffs must demonstrate a workable, class-wide damages methodology at the certification stage. This decision reinforces heightened standards for class certification that parallel evolving requirements in Canadian securities litigation, where courts increasingly demand concrete evidence and specific liability theories before approving class actions.
CanadaLitigation, Mediation & Arbitration
Blake, Cassels & Graydon LLP
Blake, Cassels & Graydon LLP
Article

Lessons In Suing Securities Regulators: Herner v. Mutual Fund Dealers Association And Ontario Securities Commission, 2026 ONSC 4889

A mutual fund dealing representative sued the MFDA and OSC for $47.5 million in damages, alleging intentional torts including conspiracy, abuse of process, and malicious prosecution stemming from a regulatory investigation and enforcement proceedings. The 21-day trial resulted in complete dismissal of all claims, with the court making significant findings on regulatory immunity provisions and the scope of duties owed by securities regulators to regulated persons.
CanadaLitigation, Mediation & Arbitration
Crawley MacKewn Brush LLP
Crawley MacKewn Brush LLP
Article

Landmark SCC Ruling Provides Clarity On Privative Clauses

The Supreme Court of Canada has delivered a landmark ruling declaring section 66 of the Conflict of Interest Act unconstitutional, fundamentally reshaping the boundaries between legislative authority and judicial oversight of administrative decisions. This unanimous decision addresses longstanding questions about the validity of privative clauses that restrict courts' ability to review findings by Parliament's ethics commissioner.
CanadaLitigation, Mediation & Arbitration
Torys
Torys
Article

A KTEP Ahead: Canada's New Mechanism For Advanced Examination Of Patent Applications

For a Canadian patent application to be examined, an applicant must file a request for examination with the Canadian Intellectual Property Office (CIPO). In most cases, the order in which applications are examined is based on the order that the requests for examination are received. An applicant may be able to accelerate examination of their patent application through several existing mechanisms, including advancing examination via special order, accelerating examination of applications related to green technology, and the Patent Prosecution Highway (PPH).
CanadaIntellectual Property
Smart & Biggar
Smart & Biggar
Article

PMPRB Consults Further On Revised Proposed Practice Directions

The Patented Medicine Prices Review Board (PMPRB) has launched a second 30-day consultation on revised proposed Practice Directions for hearings related to excessive medicine pricing and compliance with filing requirements. The revised directions incorporate feedback from the initial consultation, with a summary chart detailing all edits available for stakeholder review.
CanadaFood, Drugs, Healthcare, Life Sciences
Smart & Biggar
Smart & Biggar
Article

Canada’s Drug Agency: Guidance Document On Use Of AI Methods & Summary Of Precision Medicine Initiatives

Canada's Drug Agency has released new guidance on using artificial intelligence methods to generate real-world evidence for health technology assessments, establishing governance considerations and appraisal principles that emphasize transparency, human oversight, and validation. The agency also launched initiatives supporting precision medicine decision-making, including testing procedure assessments and a pan-Canadian framework for biomarker evaluation in cancer care.
CanadaFood, Drugs, Healthcare, Life Sciences
Smart & Biggar
Smart & Biggar
Article

New Regulatory Amendments Formalize Updates To The Drug And Medical Device Shortages Framework

Health Canada has published comprehensive amendments to drug and medical device shortage regulations, introducing expanded reporting requirements, extended expiration date authorities, and enhanced exceptional importation frameworks. The new measures grant the Minister of Health broader powers to prevent and respond to supply disruptions while requiring manufacturers to provide 12-month advance notice of discontinuations.
CanadaFood, Drugs, Healthcare, Life Sciences
Smart & Biggar
Smart & Biggar
Article

Mise à jour sur les instruments médicaux : modernisation des LEIM, demandes d’homologation d’instruments médicaux de classe III et IV, et rapports sur le rendement de la Direction des instruments médicaux

Santé Canada modernise son processus d'octroi de licences d'établissement d'instruments médicaux avec des modifications réglementaires majeures entrant en vigueur en décembre 2026. Ces changements visent à alléger le fardeau réglementaire, promouvoir l'innovation et améliorer la compétitivité de l'industrie canadienne des dispositifs médicaux.
CanadaFood, Drugs, Healthcare, Life Sciences
Smart & Biggar
Smart & Biggar
Article

Santé Canada obtient une injonction permanente visant à empêcher Canlab Research de vendre illégalement des peptides injectables

Santé Canada a obtenu une injonction permanente contre Canlab Research, interdisant la vente de peptides injectables non autorisés au Canada. Cette décision fait suite à des mesures coercitives répétées visant à protéger les consommateurs contre des produits non homologués présentant des risques graves pour la santé.
CanadaFood, Drugs, Healthcare, Life Sciences
Smart & Biggar
Smart & Biggar